TY  - JOUR
A1  - Kirsten, Natalia
A1  - Ohm, Frenz
A1  - Gehrdau, Kathrin
A1  - Girbig, Gefion
A1  - Stephan, Brigitte
A1  - Ben-Anaya, Nesrine
A1  - Pinter, Andreas
A1  - Bechara, Falk G.
A1  - Presser, Dagmar
A1  - Zouboulis, Christos C.
A1  - Augustin, Matthias
T1  - Switching from adalimumab originator to biosimilar in patients with hidradenitis suppurativa results in losses of response — data from the German HS registry HSBest
JF  - Life
N2  - Since 2021, adalimumab biosimilar ABP 501 can be used alternatively to adalimumab originator (ADAO) in the treatment of hidradenitis suppurativa (HS). Effectiveness and safety data remain scarce. We investigated the impact of switching from ADAO to ABP 501 on disease severity and the occurrence of adverse events (AEs) in patients with HS. We analyzed clinical data on patients enrolled in the German HSBest registry. Evaluation outcomes were assessed at three time points (baseline of originator (t0), prior to switching to biosimilar (t1) and 12 to 14 weeks after switching (t2)) and included patient-reported AEs and disease severity using the International Hidradenitis Suppurativa Severity Score System (IHS4) score. In total, 94 patients were switched from ADAO to ABP 501. Overall, 33.3% (n = 31/94) of the patients developed AEs and/or loss of response (LoR) within 12 to 14 weeks after switching. Of these, 61.3% (n = 19/31) experienced LoR but no AEs, 22.6% (n = 7/31) LoR combined with AEs and 16.1% (n = 5/31) AEs only. Our study showed that switching HS patients from ADAO to ABP 501 does significantly affect treatment effectiveness. Switching patients who are on remission maintenance therapy should be viewed critically.
KW  - hidradenitis suppurativa
KW  - biologics
KW  - TNF alpha
KW  - adverse drug reaction
KW  - biosimilar
KW  - drug effectiveness
KW  - switching
KW  - adalimumab
KW  - registry
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-288213
SN  - 2075-1729
VL  - 12
IS  - 10
ER  - 
TY  - JOUR
A1  - Frings, Verena Gerlinde
A1  - Schöffski, Oliver
A1  - Goebeler, Matthias
A1  - Presser, Dagmar
T1  - Economic analysis of the costs associated with Hidradenitis suppurativa at a German University Hospital
JF  - PLoS One
N2  - Background and objectives
Hidradenitis suppurativa (HS) significantly affects the patient`s quality of life and leads to multiple medical consultations. Aim of this study was to assess the utilization of medical care of HS patients.

Patients and methods
All patients presenting in 2017 for an outpatient, day patient and / or inpatient treatment with leading claim type HS at the Department of Dermatology, University Hospital Würzburg, were included. Primary outcome was the economic burden of HS patients, measured by resource utilization in €.

Results
The largest share of the direct medical costs for HS were the inpatient costs with a leading surgical diagnosis-related group (DRG). Antiseptics were the predominant topical prescription. While doxycycline was the most frequently prescribed systemic therapy, adalimumab was the main cost driver. The difference between in-patient (€ 110.25) and outpatient (€ 26.34) direct non-medical costs was statistically significant (p < 0.001). With regards to indirect medical costs, a statistically significantly higher loss of gross value added (inpatient mean € 1,827.00; outpatient mean € 203.00) and loss of production (inpatient mean € 1,026.00; outpatient mean € 228.00) could be noted (p < 0.001), respectively.

Conclusions
The present study on disease-specific costs of HS confirms that the hospital care of patients with this disease is cost-intensive. However, the primary goal of physicians is not and should not be to save costs regarding their patients`treatment, but rather the premise to utilize the existing resources as efficient as possible. Reducing the use of costly therapeutics and inpatient stays therefore requires more effective therapy options with an improved cost-benefit profile.
KW  - inpatients
KW  - outpatients
KW  - health insurance
KW  - dermatology
KW  - surgical and invasive medical procedures
KW  - health economics
KW  - psoriasis
KW  - indirect costs
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-261668
VL  - 16
IS  - 8
ER  -